# GSK Agrees to Acquire Nuvalent for $10.6 Billion to Expand Precision Oncology Pipeline

> ma · REPORTED · 2026-06-09

On June 9, 2026, GSK announced a definitive agreement to acquire Boston-based clinical-stage biopharma Nuvalent for $10.6 billion at $124 per share, a 40% premium. The deal gives GSK two late-stage best-in-class ROS1 and ALK inhibitors for non-small cell lung cancer currently under FDA review for 2026 approval.

- Company: GSK / Nuvalent
- Sector: oncology
- Primary source: https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.